A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study of CNSA-001 in Women With Moderate to Severe Diabetic Gastroparesis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs CNSA-001 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Censa Pharmaceuticals
- 16 Sep 2019 Planned End Date changed from 30 Sep 2019 to 8 Oct 2019.
- 16 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2019 Planned End Date changed from 31 Aug 2019 to 30 Sep 2019.